Shenzhou Cell (688520.SH) subsidiary product SCT640C obtained drug clinical trial approval

Zhitongcaijing · 07/24/2025 08:09

Zhitong Finance App News, Shenzhou Cell (688520.SH) issued an announcement. Recently, Shenzhou Cell Engineering Co., Ltd. (hereinafter referred to as the “Company”), a holding subsidiary of Beijing Shenzhou Cell Biotechnology Group Co., Ltd., received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration (hereinafter referred to as the “State Drug Administration”) and agreed to carry out clinical trials of the SCT640C injection, a product independently developed by the company.